NCT02503176终止3 期
An Extension Study of KCT-0809 in Dry Eye Patients With Sjögren's Syndrome
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 终止
- 主要终点
- Incidences of adverse events
研究概览
简要总结
The purpose of this study is to evaluate of the long-term safety and efficacy of KCT-0809 in dry eye patients with Sjögren's syndrome.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Dry eye patients with Sjögren's syndrome finished KCT1301 study
排除标准
- •Patients with poor adherence to medication of study drug in KCT1301 study
研究组 & 干预措施
KCT-0809
Experimental
干预措施: KCT-0809 ophthalmic solution (Drug)
结局指标
主要结局
Incidences of adverse events
时间窗: 52 weeks
次要结局
- Score of the corneal staining(52 weeks)
研究者
相似试验
已完成
3 期
A Long-term Study of KCT-0809 in Dry Eye Patients With Sjögren's SyndromeDry Eye With Sjögren's SyndromeNCT02503163Kissei Pharmaceutical Co., Ltd.
已完成
3 期
A Phase III Study of KCT-0809 in Dry Eye Patients With Sjögren's SyndromeDry Eye With Sjögren's SyndromeNCT02503189Kissei Pharmaceutical Co., Ltd.
已完成
2 期
A Phase II Study of KCT-0809 in Patients With Dry Eye SyndromeDry Eye SyndromesNCT01427816Kissei Pharmaceutical Co., Ltd.180
已完成
3 期
Study to Evaluate the Efficacy and Safety of CKD-352Dry Eye DiseaseNCT04548427Chong Kun Dang Pharmaceutical283
Unknown
3 期
Study to Evaluate the Efficacy and Safety of CKD-350Dry Eye SyndromeNCT02777723Chong Kun Dang Pharmaceutical138